Geraldine Rühl1, Anna G Niedl1, Atanas Patronov1, Katherina Siewert1, Stefan Pinkert1, Maria Kalemanov1, Manuel A Friese1, Kathrine E Attfield1, Iris Antes1, Reinhard Hohlfeld1, Klaus Dornmair1. 1. Institute of Clinical Neuroimmunology (G.R., A.G.N., K.S., R.H., K.D.) and Munich Cluster for Systems Neurology (SyNergy) (R.H., K.D.), Ludwig-Maximilian-University, Munich; Department of Life Sciences (A.P., M.K., I.A.), Technical University Munich, Freising; Max Planck Institute of Biochemistry (S.P.), Martinsried; Institute of Neuroimmunology and Multiple Sclerosis (M.A.F.), University Medical Centre, Hamburg-Eppendorf, Hamburg, Germany; MRC Human Immunology Unit (K.E.A.), Radcliffe Department of Medicine, Weatherall, Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, UK; and Center for Integrated Protein Science Munich (CIPSM) (I.A.), Germany.
Abstract
OBJECTIVE: To identify target antigens presented by human leukocyte antigen (HLA)-A*02:01 to the myelin-reactive human T-cell receptor (TCR) 2D1, which was originally isolated from a CD8+ T-cell clone recognizing proteolipid protein (PLP) in the context of HLA-A*03:01, we employed a new antigen search technology. METHODS: We used our recently developed antigen search technology that employs plasmid-encoded combinatorial peptide libraries and a highly sensitive single cell detection system to identify endogenous candidate peptides of mice and human origin. We validated candidate antigens by independent T-cell assays using synthetic peptides and refolded HLA:peptide complexes. A molecular model of HLA-A*02:01:peptide complexes was obtained by molecular dynamics simulations. RESULTS: We identified one peptide from glycerolphosphatidylcholine phosphodiesterase 1, which is identical in mice and humans and originates from a protein that is expressed in many cell types. When bound to HLA-A*02:01, this peptide cross-stimulates the PLP-reactive HLA-A3-restricted TCR 2D1. Investigation of molecular details revealed that the peptide length plays a crucial role in its capacity to bind HLA-A*02:01 and to activate TCR 2D1. Molecular modeling illustrated the 3D structures of activating HLA:peptide complexes. CONCLUSIONS: Our results show that our antigen search technology allows us to identify new candidate antigens of a presumably pathogenic, autoreactive, human CD8+ T-cell-derived TCR. They further illustrate how this TCR, which recognizes a myelin peptide bound to HLA-A*03:01, may cross-react with an unrelated peptide presented by the protective HLA class I allele HLA-A*02:01.
OBJECTIVE: To identify target antigens presented by humanleukocyte antigen (HLA)-A*02:01 to the myelin-reactive humanT-cell receptor (TCR) 2D1, which was originally isolated from a CD8+ T-cell clone recognizing proteolipid protein (PLP) in the context of HLA-A*03:01, we employed a new antigen search technology. METHODS: We used our recently developed antigen search technology that employs plasmid-encoded combinatorial peptide libraries and a highly sensitive single cell detection system to identify endogenous candidate peptides of mice and human origin. We validated candidate antigens by independent T-cell assays using synthetic peptides and refolded HLA:peptide complexes. A molecular model of HLA-A*02:01:peptide complexes was obtained by molecular dynamics simulations. RESULTS: We identified one peptide from glycerolphosphatidylcholine phosphodiesterase 1, which is identical in mice and humans and originates from a protein that is expressed in many cell types. When bound to HLA-A*02:01, this peptide cross-stimulates the PLP-reactive HLA-A3-restricted TCR 2D1. Investigation of molecular details revealed that the peptide length plays a crucial role in its capacity to bind HLA-A*02:01 and to activate TCR 2D1. Molecular modeling illustrated the 3D structures of activating HLA:peptide complexes. CONCLUSIONS: Our results show that our antigen search technology allows us to identify new candidate antigens of a presumably pathogenic, autoreactive, humanCD8+ T-cell-derived TCR. They further illustrate how this TCR, which recognizes a myelin peptide bound to HLA-A*03:01, may cross-react with an unrelated peptide presented by the protective HLA class I allele HLA-A*02:01.
Authors: Y Zhao; B Gran; C Pinilla; S Markovic-Plese; B Hemmer; A Tzou; L W Whitney; W E Biddison; R Martin; R Simon Journal: J Immunol Date: 2001-08-15 Impact factor: 5.422
Authors: Whitney A Macdonald; Zhenjun Chen; Stephanie Gras; Julia K Archbold; Fleur E Tynan; Craig S Clements; Mandvi Bharadwaj; Lars Kjer-Nielsen; Philippa M Saunders; Matthew C J Wilce; Fran Crawford; Brian Stadinsky; David Jackson; Andrew G Brooks; Anthony W Purcell; John W Kappler; Scott R Burrows; Jamie Rossjohn; James McCluskey Journal: Immunity Date: 2009-12-18 Impact factor: 31.745
Authors: Heather L E Lang; Helle Jacobsen; Shinji Ikemizu; Christina Andersson; Karl Harlos; Lars Madsen; Peter Hjorth; Leif Sondergaard; Arne Svejgaard; Kai Wucherpfennig; David I Stuart; John I Bell; E Yvonne Jones; Lars Fugger Journal: Nat Immunol Date: 2002-09-03 Impact factor: 25.606
Authors: Christian Skulina; Stephan Schmidt; Klaus Dornmair; Holger Babbe; Axel Roers; Klaus Rajewsky; Hartmut Wekerle; Reinhard Hohlfeld; Norbert Goebels Journal: Proc Natl Acad Sci U S A Date: 2004-02-24 Impact factor: 11.205
Authors: Boel Brynedal; Kristina Duvefelt; Gudrun Jonasdottir; Izaura M Roos; Eva Akesson; Juni Palmgren; Jan Hillert Journal: PLoS One Date: 2007-07-25 Impact factor: 3.240
Authors: Amin Ziaei; Amy M Lavery; Xiaorong Ma Shao; Cameron Adams; T Charles Casper; John Rose; Meghan Candee; Bianca Weinstock-Guttman; Greg Aaen; Yolanda Harris; Jennifer Graves; Leslie Benson; Mark Gorman; Mary Rensel; Soe Mar; Tim Lotze; Benjamin Greenberg; Tanuja Chitnis; Janace Hart; Amy T Waldman; Lisa F Barcellos; Emmanuelle Waubant Journal: Mult Scler Date: 2022-01-08 Impact factor: 5.855
Authors: Emmanuelle Waubant; Robyn Lucas; Ellen Mowry; Jennifer Graves; Tomas Olsson; Lars Alfredsson; Annette Langer-Gould Journal: Ann Clin Transl Neurol Date: 2019-08-07 Impact factor: 4.511